3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
3
Oropharyngeal Neoplasms
3
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Mouth Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage III Lung Non-Small Cell Cancer AJCC v7
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Fluorodeoxyglucose F18
×
90 days
×
Clear all
No trials found.